Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients

@inproceedings{Vanderwalde2018MicrosatelliteIS,
  title={Microsatellite instability status determined by next‐generation sequencing and compared with PD‐L1 and tumor mutational burden in 11,348 patients},
  author={Ari M Vanderwalde and David Spetzler and Nianqing Xiao and Zoran Gatalica and John Marshall},
  booktitle={Cancer medicine},
  year={2018}
}
Microsatellite instability (MSI) testing identifies patients who may benefit from immune checkpoint inhibitors. We developed an MSI assay that uses data from a commercially available next-generation sequencing (NGS) panel to determine MSI status. The assay is applicable across cancer types and does not require matched samples from normal tissue. Here, we describe the MSI-NGS method and explore the relationship of MSI with tumor mutational burden (TMB) and PD-L1. MSI examined by PCR fragment… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 25 references

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

The New England journal of medicine • 2015
View 4 Excerpts
Highly Influenced

Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP)

M. J. Hall, K. Gowen, +3 authors J. Kaczmar
J. Clin. Oncol • 2017
View 1 Excerpt

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2016

Similar Papers

Loading similar papers…